Search results (70)
« Back to NewsUnique study of vascular disease reaches 20th anniversary
19 April 2022
Research Highlights Strategic Developments
The only project of its kind anywhere that studies patients with all types of acute vascular events - including strokes, heart attacks, aneurysms - in order to develop better diagnostic tests and treatments celebrates its 20th anniversary this month.
New funding awarded to study persistent pain in inflammatory arthritis
25 March 2022
Major Funding Awards Strategic Developments
The £3.9M Wellcome Collaborative Award will be used to identify the drivers of pain in people living with rheumatoid arthritis.
Massive Publicity for Study of Effects of Mild COVID on Smell
7 March 2022
Research Highlights Strategic Developments
Researchers from the University of Oxford have used data from UK Biobank participants to look at changes to the brain on average 4.5 months after mild SARS-CoV-2 infection.
NIHR Awards Oxford Health Clinical Research Facility £4 million Over Next Five Years
7 March 2022
Major Funding Awards Strategic Developments
The Oxford Health Clinical Research Facility (OH CRF) is one of 28 facilities across England to benefit from nearly £161 million that has been awarded by the National Institute for Health Research (NIHR) to expand early phase clinical research delivery in NHS hospitals.
Next Radcliffe Department of Medicine Head appointed
15 February 2022
Professor Keith Channon has been appointed as the next Head of the Radcliffe Department of Medicine (RDM).
Kia Nobre steps down as Head of Department
10 January 2022
Matthew Rushworth replaces Kia Nobre as interim Head of the Department of Experimental Psychology
New spinout company: Human-Centric Drug Discovery
7 January 2022
Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.
New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases
3 November 2021
Research Highlights Strategic Developments
Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.
Experimental Medicine and Industry Partnership
1 November 2021
The recent launch event of the Experimental Medicine Industry Partnership was an exciting collaboration between industry representatives and researchers from the University of Oxford. During the event, a series of workshops were held to discuss opportunities, challenges, and future directions for the application of experimental medicine in psychiatric drug development.
Major research network to investigate body clock and stroke
27 October 2021
Major Funding Awards Research Highlights Strategic Developments
The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.
Mapping uncharted networks in the progression of Parkinson’s
27 October 2021
Major Funding Awards Strategic Developments
A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between a core team of Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institute, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.
Researchers awarded Wellcome Innovator Grant to investigate role of brainstem nucleus in human consciousness
25 October 2021
Major Funding Awards Strategic Developments
Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.
New appointments in Experimental Psychology
10 September 2021
The Department of Experimental Psychology has recruited two senior researchers.
Lecture Theatre renamed to honour Sir Colin Blakemore FRS
16 August 2021
Awards and Honours Strategic Developments
The Large Lecture Theatre in the Sherrington Building is being renamed the Blakemore Lecture Theatre in tribute to the longest serving Waynflete Professor of Physiology Sir Colin Blakemore FRS following a prestigious Festschrift event held in Professor Blakemore's honour.
Continued ethical animal research needed to advance treatment of brain disease, researchers argue
5 August 2021
Research Highlights Strategic Developments
More research is needed to improve the treatment of brain diseases such as depression, Alzheimer’s or ADHD. A widely held view within the scientific community is that this cannot be done without ethically conducted animal research.
£36 Million Boost for AI Technologies to Revolutionise NHS Care
24 June 2021
Major Funding Awards Research Highlights Strategic Developments
An Oxford project using artificial intelligence to develop digital triage tools for mental health clinicians (CHRONOS) is one of 38 projects support by the second wave of the NHS AI Lab's AI in Health and Care Award.
New Head of the Department of Psychiatry – Professor Belinda Lennox
11 June 2021
Research Highlights Strategic Developments
Professor Belinda Lennox has been welcomed to the role of Head of the Department of Psychiatry at the University of Oxford and will take over leadership in October 2021.
New Transatlantic Partnership in Mental Health
23 April 2021
The new partnership between Oxford Health NHS Foundation Trust, the University of Oxford, the University of Toronto, and the Centre for Addiction and Mental Health (CAMH) in Toronto, will enable the development of key structures to facilitate collaboration.